Stock_Titan Posted - 16 hours ago

$RGNX REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights https://www.stocktitan.net/news/RGNX/regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-b77nm2fddog8.html

chivo12 Posted - 04/29/24

$RGNX doesn’t some interim study data get released next week at ARVO 2024 annual meeting? I think I recollect something about that being mentioned a few months ago but can’t find where I thought I heard /read it.

Stock_Titan Posted - 04/24/24

$RGNX REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit https://www.stocktitan.net/news/RGNX/regenxbio-to-participate-in-chardan-s-8th-annual-genetic-medicines-ej5o3lmv60n4.html

WaveRB77 Posted - 04/22/24

$RGNX interest rates,debt,war !!!

BRITLS Posted - 04/18/24

$RGNX what a shit show. sure lost the pop up last month fast.

insiderbuyingselling Posted - 04/17/24

$RGNX new insider selling: 15000 shares. http://insiderbuyingselling.com/?t=RGNX

Aigner_Andreas Posted - 04/04/24

TD BUY $RGNX at 19.15, Supp 19.15 Resis 22.51 R18 HiLo 56% T1Y 48 buy 2.1 DIV N/A #Regenxbio #stocks #trading #finance #market

waterlock Posted - 04/02/24

$RGNX Has the 140M offering closed? They said it should be closed on March 11th. At the current price, I do think it is a bit overvalued. They have a serious patent problem. (previously lost to $SRPT )

DonCorleone77 Posted - 03/28/24

$RGNX Regenxbio's ABBV-RGX-314 featured in published study for wet AMD Regenxbio announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration - wet AMD -. These positive study results informed the ongoing pivotal trials of ABBV-RGX-314, a potential one-time gene therapy, for the treatment of wet AMD. The findings in The Lancet demonstrated that a single administration of ABBV-RGX-314 was generally well tolerated. Stable or improved visual acuity and retinal thickness was observed with few or no supplemental anti-VEGF injections in most patients at two years. Patients who received therapeutic doses demonstrated sustained levels of ABBV-RGX-314 protein and stable or improved vision and retinal anatomy with few, to no, supplemental anti-VEGF injections in most participants up to two years....

Stock_Titan Posted - 03/28/24

$RGNX REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD https://www.stocktitan.net/news/RGNX/regenxbio-announces-lancet-publication-of-phase-i-i-ia-study-zorxbnpw526g.html

Stock_Titan Posted - 03/27/24

$RGNX REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days https://www.stocktitan.net/news/RGNX/regenxbio-to-participate-in-cantor-fitzgerald-s-virtual-dmd-and-b64jtpnghdnc.html

BRITLS Posted - 03/22/24

$RGNX lol 1 share traded at 20.5

Udbsbzis Posted - 03/18/24

$RGNX hey Ken mills… Needed to sell more. You fucking piece of shit. Enjoy the new Lamborghini

WaveRB77 Posted - 03/15/24

$RGNX can any news get this stock moving.

maphere Posted - 03/13/24

$CLSD $RGNX Listen up AH for hints of PH3 RGX-314 via suprachoroidal... MAR 13, 2024 AT 4:05 PM EDT BARCLAYS 26TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Link below for fireside chat CLICK HERE FOR WEBCAST https://regenxbio.gcs-web.com/events

BRITLS Posted - 03/12/24

$RGNX that's a big volume candle ha

G101SPM Posted - 03/11/24

$RGNX $23.36 bid. DAC (dollar average cost) 18.88 (2.27.24). EXIT $35.00. UPDATE: .C. Wainwright initiates RGNX with a Buy and price target of $36. Analyst Yi Chen said, "REGENXBIO is a clinical-stage biotechnology company focused on the development of gene therapies that enable the production of therapeutic proteins or antibodies for ophthalmic disorders and rare diseases. The drug candidates use adeno-associated virus (AAV) vectors from the company's proprietary gene delivery platform—NAV® technology platform, which consists of exclusive rights to a large portfolio of AAV vectors, including AAV8 and AAV9 among others. NAV is a clinically and commercially validated platform. Zolgensma®, developed on the NAV AAV9 vector and marketed by Novartis for the treatment of spinal muscular atrophy (SMA), generated $1.2B of net sales in 2023.

G101SPM Posted - 03/11/24

$RGNX $22.75 last bid. DAC $18.99 (2.28.24). EXIT $35.00. UPDATE: REGENXBIO Inc.(RGNX) today announced it will participate the following upcoming investor conferences: Leerink Partners 2024 Global Biopharma Conference Date: Tuesday, March 12, 2024 Location: Miami, FL 1x1 investor meetings only Barclays 26th Annual Global Healthcare Conference Fireside Chat: Wednesday, March 13, 2024 at 4:05 p.m. ET Gene Therapy Regulatory Path in Rare Diseases Panel: Wednesday, March 13, 2024 at 4:35 p.m. ET Location: Miami, FL UBS Virtual CNS Day Fireside Chat: Monday, M

Stock_Titan Posted - 03/11/24

$RGNX REGENXBIO to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/RGNX/regenxbio-to-participate-in-upcoming-investor-myn8kcb3gwtq.html

DonCorleone77 Posted - 03/07/24

$RGNX Regenxbio 4.57M share Spot Secondary priced at $23.00 The deal size was increased to $140M in common stock from $125M in common stock. Morgan Stanley, Goldman Sachs, Barclays and Stifel acted as joint book running managers for the offering.

Stock_Titan Posted - 03/06/24

$RGNX REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants https://www.stocktitan.net/news/RGNX/regenxbio-announces-pricing-of-upsized-public-offering-of-common-5g189rqd5zhz.html

BRITLS Posted - 03/06/24

$RGNX looks like we might be going back to 20$.

DonCorleone77 Posted - 03/06/24

$RGNX Regenxbio announces $125M common stock offering Regenxbio announced that it intends to offer and sell, subject to market conditions, $125M of its common stock in an underwritten public offering. Morgan Stanley, Goldman Sachs & Co., Barclays and Stifel are acting as joint book-running managers of the offering.

Stock_Titan Posted - 03/06/24

$RGNX REGENXBIO Announces Proposed Public Offering of Common Stock https://www.stocktitan.net/news/RGNX/regenxbio-announces-proposed-public-offering-of-common-hxto3yu9g3l3.html

swingingtech Posted - 03/06/24

$RGNX $SRPT $ADMA https://wallstreetwaves.com/regenxbio-rgnx-soars-15-on-interim-data-from-dmd-study/

WaveRB77 Posted - 03/06/24

$RGNX this stock always moves at the end of the day.

G101SPM Posted - 03/06/24

$RGNX $25.50. DAC $18.9 (2.27.24). EXIT $35.00. UPDATE: REGENXBIO (RGNX) upgraded to Outperform from Market Perform at Leerink Partners; tgt $37.

Ohzipit Posted - 03/05/24

$RGNX RJF update today.

G101SPM Posted - 03/05/24

$RGNX $24.10 ... Change EXIT to $35.00 (from $26.00)with new designation as Legacy Holding.

_StockTrader Posted - 03/05/24

Real-Time Stock Data $RGNX Price: 24.78 Volume: 1991818 Market Cap: 1093141120 PE Ratio: -10.294978 Stock data provided by: PSYC